Update in preventive medicine

Annals of Internal Medicine

Volumn 131, Issue 9, 1999, Pages 681-687

  Beck, Laurence H ^a   Kumar, Seema Pania ^b   Hudson, Barbara ^c  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; FOLIC ACID; GESTAGEN; MEVINOLIN; PRAVASTATIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COLON CANCER; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; ESTROGEN THERAPY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0032701099     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-9-199911020-00009     Document Type: Article

References (2)

1. Lewis SF, Sacks FM, Mitchell JS, East C, Classer S, Kell S. et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32: 140-6.
2. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC. Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-7.